Signals 07: May 2026

Welcome back to Signals, a members-only newsletter analyzing key commercial developments across the neurotech industry each month.

Following April’s Acquisition Spree, this edition covers top developments from May 2026, which produced a flurry of commercial milestones across public companies with implanted devices and private startups with non-invasive neuromod, and more in between.

• Mobia’s IPO marks a 19 year, $165M commercial journey

• Medtronic’s $650m SPR Acquisition & Neurmod’s Pain Market

• Inspire’s Updated Guidance & Coding Drama

• Galvani’s Shutdown & Limits of Corporate Innovation

• Oura Takes Two Clinical Steps With New Partnerships

• Neurovalens: 4x FDA = Neuromodulation Platform

• Ampa’s Funding Hints at a Faster TMS Future

• Neurosoft’s Funding & US Expansion Plans

Let’s dive in.

(Reminder: Unlock free access by sharing this newsletter with your network!)